Traditional Chinese medicine composite for treating immune thrombocytopenic purpura

Abstract

The invention discloses a traditional Chinese medicine composite for treating immune thrombocytopenic purpura. The traditional Chinese medicine composite is prepared from the following raw materials in parts by weight: 10-30 parts of cornu bubali, 10-30 parts of indigo naturalis, 10-30 parts of lithospermum, 10-30 parts of pseudo-ginseng, 10-30 parts of selaginella tamariscina, 10-30 parts of angelica sinensis, 1-5 parts of ginseng, 10-30 parts of astragalus mongholicus, 10-30 parts of rehmannia root, 1-5 parts of antler slices, 10-30 parts of tortoise shell, 1-5 parts of placenta hominis, 10-15 parts of radix salviae miltiorrhizae, 10-30 parts of polygonum cuspidatum and 10-20 parts of cortex moutan. The traditional Chinese medicine composite is prepared into powder, pills, pastes or tablets by weighing the raw materials in the weight proportion and using a conventional traditional Chinese preparation method. The traditional Chinese medicine composite is high in components and is quantitatively blended; the dosage form can be powder, pills, pastes or tablets; and the medicines are matched with each other, the composite has the functions of replenishing qi to invigorate the spleen, governing the blood, tonifying kidney to perform spermatogenesis and culture the blood, promoting blood circulation to remove blood stasis to generate new blood, so that the human immunocompetence can be obviously improved, the micro-circulation is improved, the blood cells are increased, and the worries and the poor reaction of the patients caused by hormonotherapy of western medicine and spleen cutting are improved.

Description

technical field [0001] The present invention relates to a traditional Chinese medicine composition, in particular to a traditional Chinese medicine composition for treating immune thrombocytopenic purpura. [0002] Background technique [0003] Purpura is a relatively common clinical sign, often caused by a decrease in the number of platelets, so it is generally called thrombocytopenic purpura. Among them, immune thrombocytopenic purpura is the most common. Although thrombotic thrombocytopenic purpura has a low incidence rate, its mortality rate is high. In the past, idiopathic thrombocytopenic purpura was considered to be a bleeding disorder of unknown cause. In recent years, a large number of studies have confirmed that the disease is related to immune response, so it should be called autoimmune thrombocytopenic purpura (also referred to as ITP). The hematological characteristics of this disease are thrombocytopenia in peripheral blood, anti-platelet antibodies bound to ...

AI Technical Summary

Problems solved by technology

[0006] Aiming at the above-mentioned deficiencies in the prior art, the purpose of the present invention is to provide a Chinese medicine composition for treating immune thrombocytopenic purpura, to impro...